Wednesday, June 17, 2020 9:41:06 AM
We expect this increase to continue and to grow in the 3rd quarter.
FemCelz® Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction
As described within our CaverStem® summary, FemCelz® was also impacted by COVID-19. We are continuing to expand our practice base and anticipate a positive incline in this business as well.
OvaStemTM Regenerative Stem Cell Procedure for Treatment of Premature Ovarian Failure
We are pleased to announce notification from the US Patent and Trademark Office that our Patent claims have been issued. The issued claims are broad and provide patent protection for the use of stem cells from multiple origins including autologous bone marrow derived stem cells and allogenic stem cells derived from sources such as amniotic fluid and cord blood.
The broad claims provide the company significant flexibility as we shall pursue the Autologous method of treatment as CaverStem® and FemCelz®. We may also pursue the Allogenic method which would require Clinical Trials and FDA approval. It is our goal to seek out a joint venture partner to execute on the Allogenic model as significant time and resources would be required.
AmnioStem™ and StemSpine®
Updates will be released soon.
$CELZ
Recent CELZ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/16/2024 04:15:14 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/04/2024 08:46:02 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2024 08:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM